Tianjin Chase Sun Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2023: USD 0.29

Tianjin Chase Sun Pharmaceutical Co.,Ltd Revenue Per Share is USD 0.29 for the year ending December 31, 2023, a -10.85% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2022 was USD 0.32, a -20.17% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2021 was USD 0.40, a 21.45% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2020 was USD 0.33, a 38.43% change year over year.
  • Tianjin Chase Sun Pharmaceutical Co.,Ltd Revenue Per Share for the year ending December 31, 2019 was USD 0.24, a 16.02% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
Shenzhen Stock Exchange: 300026.SZ

Tianjin Chase Sun Pharmaceutical Co.,Ltd

CEO Ms. Dan Zheng
IPO Date Oct. 30, 2009
Location China
Headquarters No. 20, Quanfa Road
Employees 5,910
Sector Health Care
Industries
Description

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, medicinal granules, synthetic drugs, biotech drugs, medical apparatus, and Internet based therapy. It is also involved in the research and development of various drugs in the areas of sepsis, pulmonary hypertension, leukemia, cardiovascular and cerebrovascular diseases, arthritis, ischemic stroke, HCV, vascular disease, psychosis, and chemotherapy, as well as anesthesia drugs and immunomodulators. The company was founded in 1996 and is based in Tianjin, China.

StockViz Staff

January 15, 2025

Any question? Send us an email